S Bank Fund Management Ltd Sells 327 Shares of Neurocrine Biosciences, Inc. $NBIX

S Bank Fund Management Ltd reduced its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 25.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 965 shares of the company’s stock after selling 327 shares during the period. S Bank Fund Management Ltd’s holdings in Neurocrine Biosciences were worth $121,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Aware Super Pty Ltd as trustee of Aware Super lifted its stake in shares of Neurocrine Biosciences by 141.2% during the 2nd quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 37,795 shares of the company’s stock valued at $4,750,000 after buying an additional 22,125 shares in the last quarter. Generali Asset Management SPA SGR lifted its stake in shares of Neurocrine Biosciences by 296.6% during the 2nd quarter. Generali Asset Management SPA SGR now owns 29,065 shares of the company’s stock valued at $3,653,000 after buying an additional 21,736 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Neurocrine Biosciences by 24.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 3,273 shares of the company’s stock valued at $411,000 after buying an additional 645 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at approximately $342,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Neurocrine Biosciences by 15.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 447,900 shares of the company’s stock valued at $57,331,000 after buying an additional 60,094 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $137.52 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $154.61. The stock has a market capitalization of $13.64 billion, a PE ratio of 40.69, a P/E/G ratio of 0.99 and a beta of 0.21. The company’s 50 day simple moving average is $138.35 and its two-hundred day simple moving average is $125.73.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The business had revenue of $687.50 million for the quarter, compared to analysts’ expectations of $653.09 million. During the same period in the prior year, the company posted $1.63 EPS. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NBIX. Zacks Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Stifel Nicolaus upped their price target on shares of Neurocrine Biosciences from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. Finally, Needham & Company LLC upped their price target on shares of Neurocrine Biosciences from $161.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, September 22nd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $163.44.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 106,322 shares of the firm’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the sale, the director owned 514,596 shares in the company, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.80% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.